Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Blood

Volumn 108, Issue 8, 2006, Pages 2540-2544

  Sebban, Catherine ^a   Mounier, Nicolas ^b   Brousse, Nicole ^b   Belanger, Coralie ^b   Brice, Pauline ^b   Haioun, Corinne ^b   Tilly, Herve ^b   Feugier, Pierre ^b   Bouabdallah, Redah ^b   Doyen, Chantal ^b   Salles, Gilles ^b   Coiffier, Bertrand ^b  

^a CENTRE LÉON BÉRARD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; PREDNISONE; TENIPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CHVP PROTOCOL; RECOMBINANT INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER TUMOR; BLOOD TOXICITY; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGUS TUMOR; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; KIDNEY TUMOR; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH TUMOR; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BELGIUM; COMPARATIVE STUDY; FRANCE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FRANCE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROGNOSIS; TENIPOSIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33750618068     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-013193     Document Type: Article

References (27)

1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471-1475.
2. Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol. 2001;40:213-223.
3. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer. 2002;38:1167-1172.
4. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23:2215-2223.
5. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 1995;86:3257-3262.
6. Lister TA. High-dose therapy for follicular lymphoma revisited: not if, but when? J Clin Oncol. 2003;21:3894-3896.
7. Schouten HC, Qian W, Kvaloy S, et al. High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927.
8. Tarella C, Caracciolo D, Corradini P, et al. Longterm follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia. 2000;14:740-747.
9. Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000;18:527-536.
10. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996;88:2780-2786.
11. Horning SJ, Negrin RS, Hoppe RT, et al. Highdose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
12. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105:3817-3823.
13. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667-2674.
14. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in advanced follicular lymphoma. N Engl J Med. 1993;329:1608-1614.
15. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires-86 trial. J Clin Oncol. 1998;16:2332-2338.
16. Coiffier B, Neidhardt-Berard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Ann Oncol. 1999;10:1191-1197.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
18. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
19. Sebban C, Belanger C, Brousse N, et al. Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 Trial (G.E.L.A. Study Group) [abstract]. Blood. 2003;102:104a. Abstract 354.
20. Salles GA, Foussard C, Mounier N, et al. Rituximab added to αIFN+ CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients [abstract]. Blood. 2004;104:49a. Abstract 160.
21. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
22. Coiffier B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol. 2005;3:484-505.
23. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588-1593.
24. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015-2023.
25. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6387-6393.
26. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
27. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.